Codagenix Raises $20M in Series B Funding


Codagenix, Inc., a Farmngdale, N.Y.-based clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, closed a $20m Series B funding round.

The round was led by Adjuvant Capital, with participation from Euclidean Capital and Topspin Partners.

The company intends to use the funds for the further clinical development of its live attenuated RSV vaccine for the elderly, a broadly-protective influenza vaccine and an oncolytic virus therapy for triple negative breast cancer (TNBC).

Led by CEO J. Robert Coleman, PhD, MBA, Codagenix is a clinical stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors. Its recoded vaccine candidates match to the target virus and induce an immune response to all viral antigens. For cancer, the company’s nimble platform allows them to turn a virus into a potential oncolytic immuno-oncology therapies. Codagenix spun out of the laboratory of National Academy of Science Member Eckard Wimmer at Stony Brook University in 2012.

This funding round, combined with Series A investments, brings Codagenix’s total funding to $38m. Previous funders include Topspin Partners, The Stony Brook University Center for Biotechnology and various U.S. government agencies.



Join the discussion